141 related articles for article (PubMed ID: 8291921)
21. [Spectral EEG analysis in children treated with high-dose methotrexate].
Fujii Y; Hongo T; Horikoshi Y; Mizuno Y; Ichimura M; Sugie Y; Sugie H; Igarashi Y
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):659-67. PubMed ID: 3493731
[TBL] [Abstract][Full Text] [Related]
22. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis.
Hoekstra M; Haagsma C; Neef C; Proost J; Knuif A; van de Laar M
J Rheumatol; 2006 Mar; 33(3):481-5. PubMed ID: 16463431
[TBL] [Abstract][Full Text] [Related]
23. [Effect of IV hydration with sodium bicarbonate on high-dose methotrexate disposition kinetics].
Tsuda N; Goto M; Konishi H; Yamashina H
Gan To Kagaku Ryoho; 1984 Apr; 11(4):873-80. PubMed ID: 6326682
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
25. Successful desensitization to high-dose methotrexate after systemic anaphylaxis.
Davis KA; Williams P; Walker JC
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):87-9. PubMed ID: 12546343
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
27. Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma.
Hegyi M; Gulácsi A; Cságoly E; Csordás K; Eipel OT; Erdélyi DJ; Müller J; Nemes K; Lautner-Csorba O; Kovács GT
J Cancer Res Clin Oncol; 2012 Oct; 138(10):1697-702. PubMed ID: 22652833
[TBL] [Abstract][Full Text] [Related]
28. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
29. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
[TBL] [Abstract][Full Text] [Related]
30. Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma.
Postovsky S; Ben Arush MW
Pediatr Hematol Oncol; 2005 Mar; 22(2):167-73. PubMed ID: 15805003
[TBL] [Abstract][Full Text] [Related]
31. [Bolus and maintenance infusion of high-dose methotrexate].
Amino K; Kawaguchi N; Matsumoto S; Manabe J; Tabata D; Machida M
Gan To Kagaku Ryoho; 1989 May; 16(5):2045-9. PubMed ID: 2730094
[TBL] [Abstract][Full Text] [Related]
32. [Tissue concentration of methotrexate in osteosarcoma after high-dose infusion].
Amino K
Nihon Seikeigeka Gakkai Zasshi; 1982 Aug; 56(8):765-76. PubMed ID: 6984057
[TBL] [Abstract][Full Text] [Related]
33. [Serum methotrexate determination by microbiological assay in patients receiving high-dosage methotrexate (author's transl)].
Krisch K; Kotz D; Mehta BM
Wien Klin Wochenschr; 1977 Jul; 89(14):479-81. PubMed ID: 268729
[TBL] [Abstract][Full Text] [Related]
34. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
35. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant.
Wong LS; Tymms KE; Buckley NA
Intern Med J; 2009 Jun; 39(6):379-83. PubMed ID: 19580617
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of high-dose methotrexate after intravenous administration in Chinese osteosarcoma patients from a single institution.
Zhang W; Zhang Q; Tian X; Zhao H; Lu W; Zhen J; Niu X
Chin Med J (Engl); 2015 Jan; 128(1):111-8. PubMed ID: 25563323
[TBL] [Abstract][Full Text] [Related]
37. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma. Analysis of the literature.
Delepine N; Delepine G; Bacci G; Rosen G; Desbois JC
Cancer; 1996 Nov; 78(10):2127-35. PubMed ID: 8918406
[TBL] [Abstract][Full Text] [Related]
38. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
Pongracz N; Kelaridis T; Ritschl P
Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
[TBL] [Abstract][Full Text] [Related]
39. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
40. Fever as a risk factor causing delayed elimination of methotrexate in pediatric patients receiving high doses of cancer chemotherapy.
Kagawa Y; Mukohara R; Hori H; Kawasaki H; Komada Y; Kojima M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):34-8. PubMed ID: 15024606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
